Spinocerebellar Ataxia Overview

Save information for later
Sign Up

Learn About Spinocerebellar Ataxia

View Main Condition: Movement Disorders

What is the definition of Spinocerebellar Ataxia?
Spinocerebellar ataxia is a genetic disorder that has many different types. Ataxia is a term that refers to difficulties with movement, balance, coordination, and speech. Spinocerebellar ataxia can appear at any age and is a progressive disorder.
What are the symptoms of Spinocerebellar Ataxia?
Symptoms of spinocerebellar ataxia depend on the type. Symptoms of spinocerebellar ataxia may appear suddenly or develop over time. Common symptoms of spinocerebellar ataxia include weakness, loss of sensation, and difficulty with eye movements. Additional symptoms of spinocerebellar ataxia may include back-and-forth eye movements, clumsiness, slurred speech, difficulty swallowing, loss of fine motor skills, muscle tremors, decreased coordination, difficulty walking, wide-set gait, impaired balance, frequent falls, and heart problems.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Spinocerebellar Ataxia?
There is currently no cure for spinocerebellar ataxia. Treatment for spinocerebellar ataxia depends on the type. Treatment for spinocerebellar ataxia is focused on managing the symptoms and improving mobility. Treatments for symptoms of spinocerebellar ataxia may include medications; physical therapy; occupational therapy; speech therapy; and assistive mobility devices, such as modified eating utensils, communication aids, canes, hiking sticks, walker, wheelchair, or motorized scooter.
Who are the top Spinocerebellar Ataxia Local Doctors?
Elite in Spinocerebellar Ataxia
Dr. Katherine D. Mathews
Neurology | Pediatrics | Pediatric Neurology
Elite in Spinocerebellar Ataxia
Dr. Katherine D. Mathews
Neurology | Pediatrics | Pediatric Neurology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
319-356-1616
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Mathews is a Neurologist and a Pediatrics provider in Iowa City, Iowa. Dr. Mathews is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. Her top areas of expertise are Limb-Girdle Muscular Dystrophy Type 2I, Limb-Girdle Muscular Dystrophy, Dystrophinopathy, and Friedreich Ataxia. Dr. Mathews is currently accepting new patients.

Elite in Spinocerebellar Ataxia
Dr. Susan L. Perlman
Neurology
Elite in Spinocerebellar Ataxia
Dr. Susan L. Perlman
Neurology

The Regents Of The University Of California

150 Medical Plz, 
Los Angeles, CA 
310-825-9989
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Perlman is a Neurologist in Los Angeles, California. Dr. Perlman is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. Her top areas of expertise are Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Spinocerebellar Ataxia
Dr. Jeremy D. Schmahmann
Neurology
Elite in Spinocerebellar Ataxia
Dr. Jeremy D. Schmahmann
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Schmahmann is a Neurologist in Boston, Massachusetts. Dr. Schmahmann is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. His top areas of expertise are Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Drug Induced Dyskinesia, and Gastrostomy. Dr. Schmahmann is currently accepting new patients.

View All Doctors
What are the latest Spinocerebellar Ataxia Clinical Trials?
A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene
A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene
Enrollment Status: Recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: Spinocerebellar ataxias 27B (SCA27B) is caused by an expansion of ≥ 250 GAA triplets in the FGF14 gene and accounts for 15% of cerebellar ataxias (around 500 patients in France). It is a late-onset form often presenting paroxysmal episodes of ataxia and/or diplopia. The disease progresses slowly, with an average increase of 0.10 points/year on the Friedreich's Ataxia Rating Scale (FARS) - Function...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1b First-in-Human, Open-Label, Dose-Finding Trial to Evaluate the Safety and Tolerability of SGT-212 Delivered Via Dual Intradentate Nucleus (IDN) and Intravenous (IV) Administration to Participants With Friedreich's Ataxia (FA)
A Phase 1b First-in-Human, Open-Label, Dose-Finding Trial to Evaluate the Safety and Tolerability of SGT-212 Delivered Via Dual Intradentate Nucleus (IDN) and Intravenous (IV) Administration to Participants With Friedreich's Ataxia (FA)
Enrollment Status: Recruiting
Publish Date: December 09, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.

View All Clinical Trials